Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5694/j.1326-5377.2006.tb00540.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Safety of 1 mcg/mL as the starting dose in cluster protocol for hymenoptera immunotherapy.
Allergol Immunopathol (Madr)
January 2025
Department of Allergy and Clinical Immunology, Firooz Abadi Hospital, Iran University of Medical Sciences, Tehran, Iran;
Background: Hymenoptera venom allergy is a potentially severe allergic reaction in the general population. The only preventative approach in these cases is venom immunotherapy (VIT), which follows different protocols. The recommended initial dose is 0.
View Article and Find Full Text PDFTherapeutic potential of a systemically applied humanized monoclonal antibody targeting Toll‑like receptor 2 in atopic‑dermatitis‑like skin lesions in a mouse model.
Biomed Rep
March 2025
Department of Biological Sciences, Sanghuh College of Life Science, Konkuk University, Seoul 05029, Republic of Korea.
Atopic dermatitis (AD) is a prevalent, persistent inflammatory skin disorder distinguished by pruritic and irritated skin. Toll-like receptors (TLRs) are specialized receptors that recognize specific patterns associated with pathogens and tissue damage, triggering an innate immune response that protects the host from invading pathogens. Previously, it was demonstrated that intradermal injection of the humanized anti-TLR2 monoclonal antibody (Ab) Tomaralimab effectively relieved AD-like skin inflammation in BALB/c mouse models exposed to house dust mite extracts.
View Article and Find Full Text PDFAwareness of anaphylaxis among public in Al-Ahsa City of Saudi Arabia: A cross-sectional study.
PLoS One
January 2025
Respiratory Service, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Background: Anaphylaxis is a severe, life-threatening allergic reaction requiring prompt treatment with epinephrine. However, gaps in public understanding exist globally. To guide future education efforts, this study assessed anaphylaxis awareness among adults in Al-Ahsa, Saudi Arabia.
View Article and Find Full Text PDFAccuracy of ESAT6-CFP10 skin test compared with tuberculin skin test in a healthy population: a randomized, blind, parallel controlled phase III clinical study.
BMC Infect Dis
December 2024
Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu Province, PR China.
Background: This study aimed to evaluate the diagnostic performance of ESAT6-CFP10 (EC) skin test in healthy population and determine the factors influencing the booster effect.
Methods: We conducted a randomized, double-blind, parallel controlled trial in healthy population. The experiment was divided into two stages.
[Expert consensus on subcutaneous cluster immunotherapy of inhaled allergens].
Zhonghua Yu Fang Yi Xue Za Zhi
December 2024
Allergen-specific immunotherapy is the only etiological treatment that can prevent the progression of allergic diseases at present. Cluster immunotherapy is an improved immunotherapy regimen, which shortens the dose escalation period from 4-6 months in conventional regimen to 1-8 weeks. In the past, there was no consensus or guideline to guide the standardized application of subcutaneous cluster immunotherapy of inhaled allergens in China.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!